Among pancreatic NETs, gastrinoma developed most frequently (40%) in MEN1, followed by insulinoma (10%), glucagonoma (<1%), and Vasoactive intestinal peptide tumors (VIPomas, <1%).[2] Our index patient experienced symptoms of prolactinoma in her early 20s, along with symptoms for gastrinoma and insulinomas. This evidence concerns the gene MEN1 and pancreatic neuroendocrine tumor.